GeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Rating of “Moderate Buy” from Analysts

GeneDx Holdings Corp. (NASDAQ:WGS) has earned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $96.4286.

Several brokerages recently weighed in on WGS. Guggenheim dropped their target price on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 target price on GeneDx and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Piper Sandler restated an “overweight” rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Finally, Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th.

GeneDx Price Performance

Shares of WGS stock opened at $52.21 on Monday. GeneDx has a 1-year low of $32.21 and a 1-year high of $170.87. The stock’s fifty day moving average price is $55.44 and its 200 day moving average price is $92.65. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -19.48 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The business had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. During the same quarter last year, the firm earned ($0.23) earnings per share. On average, research analysts expect that GeneDx will post -1 earnings per share for the current fiscal year.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: A federal securities class action has been filed alleging GeneDx made false and misleading statements, including claims tied to its Fabric Genomics acquisition and its impact on the company’s business and prospects. Article Title
• Negative Sentiment: Multiple law firms are now soliciting investors and advertising lead-plaintiff deadlines, signaling rising legal overhang and potential additional distraction/costs for the company. Article Title
• Neutral Sentiment: Several firms are reminding investors that the deadline to seek lead-plaintiff status in the GeneDx class action is August 3, 2026; this is mainly procedural but keeps the controversy in focus. Article Title
• Neutral Sentiment: Commentary from plaintiff firms continues to highlight the prior Q1 2026 earnings miss, the steep stock drop, and the guidance cut as evidence supporting the lawsuit, reinforcing already negative investor sentiment. Article Title
• Negative Sentiment: The lawsuit and related notices may keep investors focused on GeneDx’s earlier operational disappointment, including the revenue miss and widened losses, which remain a headwind for the stock. Article Title

Insider Buying and Selling at GeneDx

In other news, Director Keith A. Meister purchased 46,273 shares of the company’s stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $38.91 per share, for a total transaction of $1,800,482.43. Following the purchase, the director owned 4,784,570 shares in the company, valued at $186,167,618.70. This trade represents a 0.98% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 392 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $65.19, for a total value of $25,554.48. Following the sale, the chief financial officer owned 34,942 shares in the company, valued at approximately $2,277,868.98. The trade was a 1.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have bought 2,056,420 shares of company stock worth $82,035,340 and have sold 72,382 shares worth $4,889,473. Company insiders own 29.60% of the company’s stock.

Institutional Trading of GeneDx

Large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new stake in GeneDx during the 4th quarter valued at about $27,000. Jones Financial Companies Lllp grew its stake in GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the last quarter. Ramirez Asset Management Inc. purchased a new stake in GeneDx during the 4th quarter valued at about $33,000. Greenline Wealth Management LLC acquired a new position in shares of GeneDx in the 4th quarter valued at about $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of GeneDx in the 4th quarter valued at about $35,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.